Overview of the Current Status of Human Epidermal Growth Factor Receptor Inhibitors in Lung Cancer
Herbst RS, Sandler AB. Overview of the Current Status of Human Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. Clinical Lung Cancer 2004, 6: s7-s19. PMID: 15638959, DOI: 10.3816/clc.2004.s.009.Peer-Reviewed Original ResearchConceptsThird-line treatmentLung cancerMetastatic NSCLCHER1/EGFR tyrosine kinase inhibitorsPhase III placebo-controlled trialHER1/EGFR inhibitorsEpidermal growth factor receptor inhibitorsEGFR tyrosine kinase inhibitorsGrowth factor receptor inhibitorsHuman epidermal growth factor receptorAntitumor activityPlacebo-controlled trialMetastatic colorectal carcinomaPhase III trialsCell lung cancerStandard of careTyrosine kinase inhibitorsEGFR tyrosine kinase domainEpidermal growth factor receptorHuman epidermal growth factor receptor inhibitorsPhase II dataGrowth factor receptorRefractory NSCLCChemotherapy combinationsIII trials